Alnylam Pharmaceuticals, Inc.
ALNY
$332.92
$1.680.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.75% | 478.84% | -15.31% | 31.38% | 24.92% |
| Total Depreciation and Amortization | -2.15% | -1.01% | -3.20% | 1.67% | 1.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -86.11% | 69.81% | 10.00% | 70.38% | -17.00% |
| Change in Net Operating Assets | 64.26% | -508.69% | 123.07% | -100.42% | -364.00% |
| Cash from Operations | -49.69% | 111.48% | 229.93% | -24.99% | -316.58% |
| Capital Expenditure | -91.83% | 15.05% | -59.34% | 1.36% | -116.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -102.70% | 503.85% | -203.54% | 380.12% | -68.15% |
| Cash from Investing | -107.42% | 454.44% | -224.27% | 315.02% | -74.91% |
| Total Debt Issued | -100.11% | -- | -- | -- | -- |
| Total Debt Repaid | 95.42% | -- | -- | -- | -- |
| Issuance of Common Stock | -46.36% | -4.29% | 64.53% | 36.07% | -66.42% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 276.30% | -16.79% | -420.07% | 0.00% | 0.00% |
| Cash from Financing | 110.11% | -934.03% | 21.94% | 42.22% | -69.83% |
| Foreign Exchange rate Adjustments | -514.99% | -103.37% | 95.66% | 181.40% | -214.43% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -55.96% | 302.66% | 74.66% | 140.04% | -201.94% |